NEW YORK (GenomeWeb) – Cepheid is collaborating with AstraZeneca, Cubist Pharmaceuticals, and GlaxoSmithKline to develop a rapid diagnostic test that can analyze multi-drug resistant pathogens and help doctors prescribe the most beneficial antibiotics for patients.

Cepheid is currently developing the Xpert Carba-R test for assessing bacteria from rectal swab samples. The goal of the consortium is to enable the test to also analyze a variety of other biological samples, such as respiratory samples from pneumonia patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.